Specimen:
Collect
- One SST
Also Acceptable:
- One Lavender (EDTA)
- One Pink Top (EDTA)
- One Red Top
Submit
- 3 mL (Min:1.5 mL) Serum . Submit Refrigerated. Submit in a Standard Transport Tube.
Also Acceptable:
- 3 mL (Min:1.5 mL) Plasma . Submit Refrigerated. Submit in a Standard Transport Tube.
Special Handling
- Minimize air exposure
- HBsAg reflexes to HBsAg Confirmation (test# 3155) if result is Positive. Additional charges will apply.
Due to special analytical handling this panel can not be added to previously drawn specimens.
Plasma stability: 2 Days Refrigerated
For patients receiving therapy with high biotin doses (>5 mg/day), no laboratory test specimen should be collected until at least 8 hours after the last biotin administration.
Rejection Criteria
- Heat inactivated
- Turbid Specimens
Stability
Ambient: 2 Hour(s); Refrigerated: 5 Day(s); Frozen: 3 Month(s); Incubated: Unacceptable
Methodology
- Electrochemiluminescence Immunoassay, Sandwich (ECLIA)
Performed
Mon-Fri
Reported
1-3 Day(s)
CPT Codes
- 86706
- 87340
Interpretive Data
Please see report for interpretive data.
HBsAg AND ANTI-HBs INTERPRETIVE NOTES:
NEGATIVE HBsAg AND NEGATIVE ANTI-HBs: NO SEROLOGIC EVIDENCE OF HEPATITIS B VIRUS INFECTION OR IMMUNITY TO FUTURE HEPATITIS B VIRUS INFECTIONS. PATIENT IS A CANDIDATE FOR THE HEPATITIS B VACCINE.
NEGATIVE HBsAg AND POSITIVE ANTI-HBs: THE PATIENT IS CURRENTLY IMMUNE TO FUTURE INFECTION WITH HEPATITIS B VIRUS.
POSITIVE HBsAg AND NEGATIVE ANTI-HBs: CONSISTENT WITH ACTIVE (EARLY ACUTE OR LATE CHRONIC) HEPATITIS B VIRUS INFECTION. PATIENT IS INFECTIVE FOR HEPATITIS B.
POSITIVE HBsAg AND POSITIVE ANTI-HBs: THIS PATTERN MAY INDICATE CHRONIC HEPATITIS B VIRUS INFECTION. ORDER HEPATITIS B PANEL.
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may intefere with at least one test in this panel and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be taken until at least 8 hours after the last biotin administration.
HBsAg AND ANTI-HBs INTERPRETIVE NOTES:
NEGATIVE HBsAg AND NEGATIVE ANTI-HBs: NO SEROLOGIC EVIDENCE OF HEPATITIS B VIRUS INFECTION OR IMMUNITY TO FUTURE HEPATITIS B VIRUS INFECTIONS. PATIENT IS A CANDIDATE FOR THE HEPATITIS B VACCINE.
NEGATIVE HBsAg AND POSITIVE ANTI-HBs: THE PATIENT IS CURRENTLY IMMUNE TO FUTURE INFECTION WITH HEPATITIS B VIRUS.
POSITIVE HBsAg AND NEGATIVE ANTI-HBs: CONSISTENT WITH ACTIVE (EARLY ACUTE OR LATE CHRONIC) HEPATITIS B VIRUS INFECTION. PATIENT IS INFECTIVE FOR HEPATITIS B.
POSITIVE HBsAg AND POSITIVE ANTI-HBs: THIS PATTERN MAY INDICATE CHRONIC HEPATITIS B VIRUS INFECTION. ORDER HEPATITIS B PANEL.
Biotin in specimens taken from patients on high-dose biotin therapy or supplements may intefere with at least one test in this panel and cause inaccurate test results. It is recommended that for patients receiving therapy with high biotin doses (> 5 mg/day), no laboratory test specimen should be taken until at least 8 hours after the last biotin administration.
Components
- 2103 - HBsAg
- 2104 - ANTI-HBs
Last Updated: December 10, 2024 @ 10:13 am
Disclaimer:
It is preferable to locate tests on the website and not rely on printed test information, which may soon be out of date. Updated test information can only be guaranteed by using this website.
